# Silence Therapeutics plc (SLNCF) — merger/scheme_of_arrangement [pending]
Source: SEC API (secapi.ai) · situation sit_48b134a334e57c35b69a · retrieved 2026-08-16T21:06:03.543Z

## Overview
Silence Therapeutics plc is a pharmaceutical company developing therapeutic products; the filing does not provide a detailed business description beyond its status as a public company with ordinary shares and ADSs listed on Nasdaq.

Silence Therapeutics plc entered into an underwriting agreement with Jefferies LLC and Morgan Stanley & Co. LLC on August 11, 2026, to issue and sell 12,962,963 American Depositary Shares (ADSs), each representing three ordinary shares, in an underwritten public offering. The offering price to the public is $13.50 per ADS, with underwriters purchasing at $12.69 per ADS. The company granted underwriters an option to purchase up to an additional 1,944,444 ADSs within 30 days. Net proceeds are estimated at approximately $164.0 million, or approximately $188.7 million if the option is exercised in full, after deducting underwriting discounts, commissions, and estimated offering expenses. The closing is expected on August 13, 2026, subject to customary closing conditions.

## Terms
- Counterparty: Jefferies LLC and Morgan Stanley & Co. LLC (as representatives of the underwriters) · Deal value: $164.0M · Consideration: cash · Price/share: $13.5

## Key dates
- Announced 2026-08-12 · Expected close 2026-08-13

## Timeline
- 2026-08-12 · 8-K (0001193125-26-347196): 8-K - Silence Therapeutics plc — *Silence Therapeutics plc is a pharmaceutical company developing therapeutic products; the filing does not provide a detailed business description beyond its status as a public company with ordinary shares and ADSs listed on Nasdaq.* Silence Therapeutics plc entered into an underwriting agreement with Jefferies LLC and Morgan Stanley & Co. LLC on August 11, 2026, to issue and sell 12,962,963 American Depositary Shares (ADSs), each representing three ordinary shares, in an underwritten public offering. The offering price to the public is $13.50 per ADS, with underwriters purchasing at $12.69 per ADS. The company granted underwriters an option to purchase up to an additional 1,944,444 ADSs within 30 days. Net proceeds are estimated at approximately $164.0 million, or approximately $188.7 million if the option is exercised in full, after deducting underwriting discounts, commissions, and estimated offering expenses. The closing is expected on August 13, 2026, subject to customary closing conditions.
  https://www.sec.gov/Archives/edgar/data/1479615/0001193125-26-347196.txt

## Citations
- 0001193125-26-347196 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526347196